11:05 AM EDT, 10/04/2024 (MT Newswires) -- Immuron ( IMRN ) said Friday that the US Naval Medical Research Command has completed an interim analysis for the clinical evaluation of a new oral drug to treat Campylobacter and Enterotoxigenic Escherichia coli.

The NMRC funded the study and Immuron ( IMRN ) produced a hyperimmune bovine colostrum product for testing in a controlled human infection model, the company said.

The interim results showed 10.4% protective efficacy against moderate to severe campylobacteriosis, Immuron ( IMRN ) said.

The company said the results are unrelated to its Travelan drug and do not affect its plans to hold end of phase 2 meeting with the US Food and Drug Administration with a view to initiating a phase 3 clinical trial of Travelan in H2 2025.

Immuron ( IMRN ) shares were 2.6% lower in recent trading.

Price: 2.67, Change: -0.07, Percent Change: -2.55